Trademark: VYEPTI 2113137
Word
VYEPTI
Device Descrption:
2 INTERLOCKING TRIANGLES
ID
2113137
Trademark Type
Figurative
Status
Protected: Registered/protected
Application Date
19 May 2020
Registration Date
19 May 2020
Renewal Date
19 May 2030
Owner(s)
Service
WRAYS PTY LTD
Goods and Services:
Class 5:
Pharmaceuticals and medical preparations and substances; vaccines; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases in, generated by or acting on the central nervous system; pharmaceutical preparations and substances acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; pharmaceutical preparations and substances used for the prevention, management and treatment of headaches, migraines, pain, immune and inflammatory disorders and diseases; pharmaceutical preparations and substances for the prevention and treatment of dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, dyskinesia, poor or absent motor functions, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, alcoholism and dependency; preparations, substances, reagents and agents for diagnostic and medical purposes.
Pharmaceuticals and medical preparations and substances; vaccines; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases in, generated by or acting on the central nervous system; pharmaceutical preparations and substances acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; pharmaceutical preparations and substances used for the prevention, management and treatment of headaches, migraines, pain, immune and inflammatory disorders and diseases; pharmaceutical preparations and substances for the prevention and treatment of dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, dyskinesia, poor or absent motor functions, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, alcoholism and dependency; preparations, substances, reagents and agents for diagnostic and medical purposes.